@MKeykhaeiMD

PGY-2 IM Resident @DOM_UCLA| Former Postdoc @HopkinsHeart| Editorial Board @BMC_GPH, @FrontCVMedicine|🏊✈️🎹📚

 Los Angeles
scholar.google.com/citations?user=36nP1bgAAAAJ&hl=en
Joined May 2026
  • Tweets348
  • Following659
  • Followers174
9Media
1/🚨Excited to share our new study in @JACCJournals #JACCHeartFailure “National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction” shorturl.at/tnQZD My sincere gratitude goes to Dr. @gcfmd for his exceptional mentorship and guidance, and to our outstanding team for their collaboration and support: @ATSandhu @HsuePriscilla @SJGreene_md @boback @MKIttlesonMD @MattRamsisMD @uclaimchiefs @DOM_UCLA @uclaCVfellows @UCLAHealth @UCLAHealthNews #HFrEF #GDMT
16
7
41
2,285
Mohammad Keykhaei, MD, MPH retweeted
JACC Journals@JACCJournals5h
🫀ICI rechallenge after #Myocarditis: a paradigm shift? 🔎 New in #JACCCardioOnc: Emerging evidence challenges absolute contraindications. 🎯 Careful patient selection, close monitoring, and shared decisions are key! @Massimi78530343; @slumberbell bit.ly/4yGap7a
1
3
13
1,343
Mohammad Keykhaei, MD, MPH retweeted
Gregg Fonarow MD@gcfmd8h
🫀 Full quadruple GDMT for US HFrEF: 💊 4 generic pills, ~$25/month ➡️ ❤️ ~114K lives saved/year 🏥 ~864K hospitalizations avoided 💰 $16.3Billion net savings ⚠️ Only 18% get all 4 💻 One of the best opportunities in healthcare for AI to improve care, outcomes & cost?
1
2
16
551
Mohammad Keykhaei, MD, MPH retweeted
Eric H Yang, MD@datsunianOct 25
Congrats to @UCLAHealthJCCC @UCLAHealth senior author #AlexandraDrakaki for this huge accomplishment and advance for bladder cancer! @IntMedAbel @montypal @uclaimchiefs @DOM_UCLA @A_SteinMerlob
NEJM
@NEJMOct 24
Presented at #ESMO26: In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: nej.md/4z7dQFm @myESMO
A graph showing event-free survival for the durvalumab–enfortumab vedotin (EV) and control groups (intention-to-treat population).

ALT A graph showing event-free survival for the durvalumab–enfortumab vedotin (EV) and control groups (intention-to-treat population).

3
10
747
Mohammad Keykhaei, MD, MPH retweeted
Eric H Yang, MD@datsunianOct 25
Paper now out in press in the Cardio-oncology Journal in @SpringerNature link.springer.com/article/10… @DrBonnieKy @DSadlerMD @ddefariayeh

Single center experience in management of lymphoma among adult patients with Fontan circulation

Cardio-Oncology - While cancer is the fourth leading cause of mortality in adults with congenital heart disease, and despite the approximately 30,000 patients with Fontan circulation living in the...

link.springer.com
1
4
83
Mohammad Keykhaei, MD, MPH retweeted
Eric H Yang, MD@datsunianOct 25
We have published on our ACHD #cardioonc experience led by @PVenkateshMD @KimYanMD @Bravo__MD & #gentianlluri showing younger ages of dx, ⬆️ rates of cancer related mortality, and while MACE rates were ⬆️ they were manageable link.springer.com/article/10… xitter.cf/PVenkateshMD/status/15… 2/
Prashanth Venkatesh@PVenkateshMD26 Nov 2022
Excited to share our publication - the first to evaluate long-term outcomes of patients with #ACHD and cancer. Many thanks to @DOM_UCLA dream team @datsunian, Gentian Lluri, @Bravo__MD and 🌟resident @UCSFIMChiefs, @KimYanMD! rdcu.be/c0ivN
1
2
4
311
Mohammad Keykhaei, MD, MPH retweeted
Eric H Yang, MD@datsunianOct 25
The 5 pts in this case series demonstrate that there is, at least for now, no cardioprotective "size fits all" for this unique population. Registries & multi-institutional collaboration essential to build larger numbers of ACHD patients to study tx strategies & outcomes 3/
1
1
3
237
Mohammad Keykhaei, MD, MPH retweeted
Eric H Yang, MD@datsunianOct 25
In #ACHD, #Fontan pts are a unique combo of anatomy & pathophysiology that can make cardiotoxicity risk difficult to gauge & manage In this @UCLAHealth collab led by @JHHirschbaum #GentianLluri we explore the tx & outcomes in a #cardioonc case series link.springer.com/article/10… 1/
2
7
1
22
1,536
Mohammad Keykhaei, MD, MPH retweeted
Bonnie Ky, MD, MSCE, FACC@DrBonnieKyOct 23
What happens to the 🫀 during cancer therapy? In this study, proteomic and metabolomic profiling identified novel biomarkers associated with cardiac remodeling and dysfunction in #breastcancer patients receiving cardiotoxic therapies. #CardioOnc 📰tinyurl.com/25b9djck
1
18
74
3,783
Mohammad Keykhaei, MD, MPH retweeted
Eric H Yang, MD@datsunianOct 21
Our #JACCCardioonc review led by @uclaimchiefs @Tylermorad & IM res @MKeykhaeiMD & @A_SteinMerlob tackles the lesser-explored aspects of ICI myocarditis care--the outpatient care, or the aftermath. 🙏 @JACCJournals for the opportunity #bruinhearts shorturl.at/PMlfR 🧵1/
4
18
57
2,387
🧵 1/10 | Excited to share our State-of-the-Art Review in @JACCJournals #JACCCardioOnc! 🎉🫀 📖 “Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath” Huge thanks to our incredible mentors Drs. @A_SteinMerlob & @datsunian, and our amazing chief resident and co-first author @Tylermorad for their invaluable guidance and support throughout this work! 🙏🫀Special thanks to @qicong_sheng for the wonderful interview! 🎙️ @DOM_UCLA @uclaCVfellows @uclaimchiefs @UCLA @UCLAHealth 🔗 doi.org/10.1016/j.jaccao.202… #CardioOnc #Immunotherapy #Myocarditis
5
7
35
1,095
more replies
9/10 | A promising treatment strategy 🔬 @DrJESalem et al., Cancer Discovery 2023: 40 ICI-myocarditis cases. Myotoxicity deaths: 6/10 initially vs 1/30 with abatacept, ruxolitinib & respiratory screening/support. aacrjournals.org/cancerdisco…

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality...

Managing concomitant respiratory muscle involvement with mechanical ventilation and treating with abatacept and ruxolitinib may reduce severe immune checkpoint inhibitor myocarditis high fatality...

aacrjournals.org
1
1
4
128
10/10 | What's next? 🎯 ATRIUM (NCT05335928): phase III abatacept vs placebo; major cardiac events. ACHLYS (NCT05195645): phase II abatacept dose/CD86-occupancy study (completed; results awaited). Our central illustration maps the outpatient gaps. 🫀📎
2
4
87
Mohammad Keykhaei, MD, MPH retweeted
Gregg Fonarow MD@gcfmdOct 20
🫀📡 New in JACC: Heart Failure: AI-guided monitoring after HF discharge was feasible, but didn't cut re-🏨 or ED visits/readmission/death 🏥 5 VA centers | 🩹 chest patch up to 90 days Feasible ≠ effective 📉❌ #HeartFailure #DigitalHealth @JACCJournals
4
8
1
21
1,471
Load more